PROTEOMICS INTERNATIONAL LABORATORIES LTD - Announcements

0.00%

38.0¢

Market Cap $62.19M

Healthcare Biotechnology

Proteomics International Laboratories Ltd is an Australia-based medical technology... Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identified up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PIQ	March 2021 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/04/21	937.9KB	Share
PIQ	Proteomics files US FDA 513(g) regulatory submission		29/04/21	246.47KB	Share
PIQ	ISO 13485 certification received - Manufacturing Update	PRICE SENSITIVE	23/04/21	247.85KB	Share
PIQ	Exercise of Options		15/03/21	359.71KB	Share
PIQ	Investor Presentation		09/03/21	1.46MB	Share
PIQ	Exercise of Options		26/02/21	359.9KB	Share
PIQ	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	24/02/21	671.95KB	Share
PIQ	Response to Price Query	PRICE SENSITIVE	16/02/21	1.34MB	Share
PIQ	Proteomics International seeks FDA approval for PromarkerD	PRICE SENSITIVE	08/02/21	262.45KB	Share
PIQ	Update - Proposed issue of Securities - PIQ		28/01/21	26.56KB	Share
PIQ	Issue of Options and Secondary Trading Notice		28/01/21	210.17KB	Share
PIQ	Results of Meeting		28/01/21	265.06KB	Share
PIQ	December 2020 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/01/21	336.79KB	Share
PIQ	Notice of Extraordinary General Meeting/Proxy Form		22/12/20	1.37MB	Share
PIQ	Results of Meeting		26/11/20	268.25KB	Share
PIQ	AGM Investor Presentation	PRICE SENSITIVE	26/11/20	1.81MB	Share
PIQ	Middle East is next market for PromarkerD immunoassay test	PRICE SENSITIVE	12/11/20	250.62KB	Share
PIQ	PromarkerD clinical assay performance results published	PRICE SENSITIVE	05/11/20	257.86KB	Share
PIQ	Change in substantial holding - Dunlop		03/11/20	127.09KB	Share
PIQ	Change in substantial holding - Lipscombe		03/11/20	116.92KB	Share
PIQ	Proteomics receives $1.1 million in R&D tax incentive	PRICE SENSITIVE	03/11/20	215.32KB	Share
PIQ	Completion of Placement and Appendix 2A	PRICE SENSITIVE	02/11/20	360.52KB	Share
PIQ	September 2020 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/10/20	919.07KB	Share
PIQ	Notice of Annual General Meeting/Proxy Form		27/10/20	1.33MB	Share
PIQ	Proteomics International raises $6m in successful Placement	PRICE SENSITIVE	23/10/20	426.64KB	Share
PIQ	Proposed issue of Securities - PIQ		23/10/20	26.7KB	Share
PIQ	Proposed issue of Securities - PIQ	PRICE SENSITIVE	23/10/20	25.16KB	Share
PIQ	Trading Halt	PRICE SENSITIVE	21/10/20	406.68KB	Share
PIQ	First distribution agreement for PromarkerD immunoassay	PRICE SENSITIVE	16/10/20	261.96KB	Share
PIQ	PromarkerD international validation study results published		12/10/20	239.95KB	Share
PIQ	Partnership with QIMR Berghofer targets oesophageal cancer	PRICE SENSITIVE	09/10/20	243.33KB	Share
PIQ	Change of Director's Interest Notice		28/09/20	329.01KB	Share
PIQ	Annual Report to shareholders		31/08/20	8.33MB	Share
PIQ	Preliminary Final Report	PRICE SENSITIVE	31/08/20	339.44KB	Share
PIQ	Corporate Governance Statement and Appendix 4G		31/08/20	524.19KB	Share
PIQ	Investor Presentation - August 2020		26/08/20	1.66MB	Share
PIQ	Proposed issue of Securities - PIQ		18/08/20	25.77KB	Share
PIQ	Issue of Corporate Advisory Options and Secondary Trading No		18/08/20	404.95KB	Share
PIQ	June 2020 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/07/20	698.53KB	Share
PIQ	PromarkerD Intellectual Property portfolio expands	PRICE SENSITIVE	27/07/20	252.45KB	Share
PIQ	Appendix 3Y - Change of Director's Interest Notice		09/07/20	309.95KB	Share
PIQ	Updated Trading Policy		30/06/20	1.3MB	Share
PIQ	Appendix 3Y - Directors on-market purchase of shares	PRICE SENSITIVE	29/06/20	570.12KB	Share
PIQ	Appendix 2A - Exercise of Employee Options		15/06/20	368.08KB	Share
PIQ	Big pharma clinical study validates PromarkerD kidney test	PRICE SENSITIVE	15/06/20	575.1KB	Share
PIQ	Trading Halt	PRICE SENSITIVE	11/06/20	714.5KB	Share
PIQ	Updated Investor Presentation	PRICE SENSITIVE	09/06/20	1.37MB	Share
PIQ	Trading Halt	PRICE SENSITIVE	05/06/20	541.96KB	Share
PIQ	Pause in Trading	PRICE SENSITIVE	05/06/20	115.92KB	Share
PIQ	Investor Presentation - June 2020		05/06/20	1.41MB	Share
PIQ	Proteomics International receives COVID-19 research grants	PRICE SENSITIVE	25/05/20	228.43KB	Share
PIQ	Appendix 3G - Issue of Employee Options		12/05/20	152.37KB	Share
PIQ	Appendix 4C and Quarterly Report - March 2020	PRICE SENSITIVE	28/04/20	504.03KB	Share
PIQ	CE Mark for Proteomics' PromarkerD Immunoassay Kit	PRICE SENSITIVE	16/04/20	245.69KB	Share
PIQ	Proteomics expands diagnostics R&D - the Promarker Pipeline	PRICE SENSITIVE	07/04/20	597.21KB	Share
PIQ	Pause in Trading	PRICE SENSITIVE	07/04/20	115.97KB	Share
PIQ	Proteomics International expands study with US big pharma	PRICE SENSITIVE	31/03/20	262.98KB	Share
PIQ	Proposed issue of Securities - PIQ		27/03/20	25.31KB	Share
PIQ	Issue of Corporate Advisory Options		27/03/20	212.14KB	Share
PIQ	Results of Meeting		27/03/20	253.99KB	Share
PIQ	Proteomics patents biomarkers for diagnosis of endometriosis	PRICE SENSITIVE	23/03/20	229.24KB	Share
PIQ	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	27/02/20	1.29MB	Share
PIQ	Notice of Extraordinary General Meeting/Proxy Form		26/02/20	1.07MB	Share
PIQ	Response to ASX Price Query	PRICE SENSITIVE	14/02/20	379.05KB	Share
PIQ	PromarkerD presented at Australasian Proteomics conference		10/02/20	1.14MB	Share
PIQ	Appendix 4C - December 2019 Quarterly Report	PRICE SENSITIVE	29/01/20	342.43KB	Share
PIQ	Change of Share Registry		20/01/20	234.34KB	Share
PIQ	CE Mark for PromarkerD Hub predictive software for DKD	PRICE SENSITIVE	14/01/20	247.58KB	Share
PIQ	Ceasing to be a substantial holder		29/11/19	74KB	Share
PIQ	Results of Meeting		28/11/19	276.21KB	Share
PIQ	Proteomics AGM Presentation		28/11/19	1.06MB	Share
PIQ	Change in substantial holding		27/11/19	146.17KB	Share
PIQ	Change in substantial holding		26/11/19	116.11KB	Share
PIQ	Partnership provides funding for cutting-edge facility	PRICE SENSITIVE	26/11/19	265.78KB	Share
PIQ	Completion of Placement		25/11/19	517.68KB	Share
PIQ	Proteomics raises $3m in heavily oversubscribed Placement	PRICE SENSITIVE	15/11/19	249.11KB	Share
PIQ	Trading Halt	PRICE SENSITIVE	13/11/19	541.2KB	Share
PIQ	CE Mark for predictive test for diabetic kidney disease	PRICE SENSITIVE	12/11/19	272.53KB	Share
PIQ	Appendix 3B - Exercise of Employee Options		04/11/19	513.81KB	Share
PIQ	Appendix 4C - September 2019 Quarterly Report	PRICE SENSITIVE	31/10/19	429.8KB	Share
PIQ	Proteomics receives $1.1 million in R&D tax incentive	PRICE SENSITIVE	29/10/19	214.79KB	Share
PIQ	Notice of Annual General Meeting/Proxy Form		21/10/19	799.41KB	Share
PIQ	PIQ market update		21/10/19	4.63MB	Share
PIQ	Change of Director's Interest Notice		01/10/19	108.03KB	Share
PIQ	Issue of Shares under Director Fee Plan		01/10/19	396.56KB	Share
PIQ	PromarkerD IVD successfully developed and validated	PRICE SENSITIVE	17/09/19	223.04KB	Share
PIQ	Trading Halt	PRICE SENSITIVE	16/09/19	683.63KB	Share
PIQ	Pause in Trading	PRICE SENSITIVE	16/09/19	117.53KB	Share
PIQ	PromarkerD diabetic kidney disease test launched in Spain	PRICE SENSITIVE	13/09/19	232.14KB	Share
PIQ	PromarkerD test ready for launch in Europe	PRICE SENSITIVE	12/09/19	284.42KB	Share
PIQ	PromarkerD latest results published in peer reviewed journal		10/09/19	262.08KB	Share
PIQ	Annual Report to shareholders		30/08/19	7.51MB	Share
PIQ	Preliminary Final Report	PRICE SENSITIVE	30/08/19	169.34KB	Share
PIQ	Corporate Governance Statement and Appendix 4G		30/08/19	368.76KB	Share
PIQ	Appendix 4C - June 2019 Quarterly Report	PRICE SENSITIVE	30/07/19	366.92KB	Share
PIQ	PromarkerD secures TGA software approval & Indonesian patent		29/07/19	238.74KB	Share
PIQ	Proteomics secures contracts for pharmacokinetic analysis	PRICE SENSITIVE	26/07/19	234.68KB	Share
PIQ	Exercise of Options - Secondary Trading Notice & Appendix 3B		26/06/19	527.37KB	Share
PIQ	PIQ investor presentation - 121 Tech Investment Hong Kong		13/06/19	865.07KB	Share
PIQ	PromarkerD to feature at world's largest diabetes conference		07/06/19	257.46KB	Share

PIQ March 2021 Quarterly Activities Report and Appendix 4C
29/04/21	PRICE SENSITIVE	937.9KB	Share
PIQ Proteomics files US FDA 513(g) regulatory submission
29/04/21		246.47KB	Share
PIQ ISO 13485 certification received - Manufacturing Update
23/04/21	PRICE SENSITIVE	247.85KB	Share
PIQ Exercise of Options
15/03/21		359.71KB	Share
PIQ Investor Presentation
09/03/21		1.46MB	Share
PIQ Exercise of Options
26/02/21		359.9KB	Share
PIQ Appendix 4D and Interim Financial Report
24/02/21	PRICE SENSITIVE	671.95KB	Share
PIQ Response to Price Query
16/02/21	PRICE SENSITIVE	1.34MB	Share
PIQ Proteomics International seeks FDA approval for PromarkerD
08/02/21	PRICE SENSITIVE	262.45KB	Share
PIQ Update - Proposed issue of Securities - PIQ
28/01/21		26.56KB	Share
PIQ Issue of Options and Secondary Trading Notice
28/01/21		210.17KB	Share
PIQ Results of Meeting
28/01/21		265.06KB	Share
PIQ December 2020 Quarterly Activities Report and Appendix 4C
28/01/21	PRICE SENSITIVE	336.79KB	Share
PIQ Notice of Extraordinary General Meeting/Proxy Form
22/12/20		1.37MB	Share
PIQ Results of Meeting
26/11/20		268.25KB	Share
PIQ AGM Investor Presentation
26/11/20	PRICE SENSITIVE	1.81MB	Share
PIQ Middle East is next market for PromarkerD immunoassay test
12/11/20	PRICE SENSITIVE	250.62KB	Share
PIQ PromarkerD clinical assay performance results published
05/11/20	PRICE SENSITIVE	257.86KB	Share
PIQ Change in substantial holding - Dunlop
03/11/20		127.09KB	Share
PIQ Change in substantial holding - Lipscombe
03/11/20		116.92KB	Share
PIQ Proteomics receives $1.1 million in R&D tax incentive
03/11/20	PRICE SENSITIVE	215.32KB	Share
PIQ Completion of Placement and Appendix 2A
02/11/20	PRICE SENSITIVE	360.52KB	Share
PIQ September 2020 Quarterly Activities Report and Appendix 4C
28/10/20	PRICE SENSITIVE	919.07KB	Share
PIQ Notice of Annual General Meeting/Proxy Form
27/10/20		1.33MB	Share
PIQ Proteomics International raises $6m in successful Placement
23/10/20	PRICE SENSITIVE	426.64KB	Share
PIQ Proposed issue of Securities - PIQ
23/10/20		26.7KB	Share
PIQ Proposed issue of Securities - PIQ
23/10/20	PRICE SENSITIVE	25.16KB	Share
PIQ Trading Halt
21/10/20	PRICE SENSITIVE	406.68KB	Share
PIQ First distribution agreement for PromarkerD immunoassay
16/10/20	PRICE SENSITIVE	261.96KB	Share
PIQ PromarkerD international validation study results published
12/10/20		239.95KB	Share
PIQ Partnership with QIMR Berghofer targets oesophageal cancer
09/10/20	PRICE SENSITIVE	243.33KB	Share
PIQ Change of Director's Interest Notice
28/09/20		329.01KB	Share
PIQ Annual Report to shareholders
31/08/20		8.33MB	Share
PIQ Preliminary Final Report
31/08/20	PRICE SENSITIVE	339.44KB	Share
PIQ Corporate Governance Statement and Appendix 4G
31/08/20		524.19KB	Share
PIQ Investor Presentation - August 2020
26/08/20		1.66MB	Share
PIQ Proposed issue of Securities - PIQ
18/08/20		25.77KB	Share
PIQ Issue of Corporate Advisory Options and Secondary Trading No
18/08/20		404.95KB	Share
PIQ June 2020 Quarterly Activities Report and Appendix 4C
29/07/20	PRICE SENSITIVE	698.53KB	Share
PIQ PromarkerD Intellectual Property portfolio expands
27/07/20	PRICE SENSITIVE	252.45KB	Share
PIQ Appendix 3Y - Change of Director's Interest Notice
09/07/20		309.95KB	Share
PIQ Updated Trading Policy
30/06/20		1.3MB	Share
PIQ Appendix 3Y - Directors on-market purchase of shares
29/06/20	PRICE SENSITIVE	570.12KB	Share
PIQ Appendix 2A - Exercise of Employee Options
15/06/20		368.08KB	Share
PIQ Big pharma clinical study validates PromarkerD kidney test
15/06/20	PRICE SENSITIVE	575.1KB	Share
PIQ Trading Halt
11/06/20	PRICE SENSITIVE	714.5KB	Share
PIQ Updated Investor Presentation
09/06/20	PRICE SENSITIVE	1.37MB	Share
PIQ Trading Halt
05/06/20	PRICE SENSITIVE	541.96KB	Share
PIQ Pause in Trading
05/06/20	PRICE SENSITIVE	115.92KB	Share
PIQ Investor Presentation - June 2020
05/06/20		1.41MB	Share
PIQ Proteomics International receives COVID-19 research grants
25/05/20	PRICE SENSITIVE	228.43KB	Share
PIQ Appendix 3G - Issue of Employee Options
12/05/20		152.37KB	Share
PIQ Appendix 4C and Quarterly Report - March 2020
28/04/20	PRICE SENSITIVE	504.03KB	Share
PIQ CE Mark for Proteomics' PromarkerD Immunoassay Kit
16/04/20	PRICE SENSITIVE	245.69KB	Share
PIQ Proteomics expands diagnostics R&D - the Promarker Pipeline
07/04/20	PRICE SENSITIVE	597.21KB	Share
PIQ Pause in Trading
07/04/20	PRICE SENSITIVE	115.97KB	Share
PIQ Proteomics International expands study with US big pharma
31/03/20	PRICE SENSITIVE	262.98KB	Share
PIQ Proposed issue of Securities - PIQ
27/03/20		25.31KB	Share
PIQ Issue of Corporate Advisory Options
27/03/20		212.14KB	Share
PIQ Results of Meeting
27/03/20		253.99KB	Share
PIQ Proteomics patents biomarkers for diagnosis of endometriosis
23/03/20	PRICE SENSITIVE	229.24KB	Share
PIQ Appendix 4D and Interim Financial Report
27/02/20	PRICE SENSITIVE	1.29MB	Share
PIQ Notice of Extraordinary General Meeting/Proxy Form
26/02/20		1.07MB	Share
PIQ Response to ASX Price Query
14/02/20	PRICE SENSITIVE	379.05KB	Share
PIQ PromarkerD presented at Australasian Proteomics conference
10/02/20		1.14MB	Share
PIQ Appendix 4C - December 2019 Quarterly Report
29/01/20	PRICE SENSITIVE	342.43KB	Share
PIQ Change of Share Registry
20/01/20		234.34KB	Share
PIQ CE Mark for PromarkerD Hub predictive software for DKD
14/01/20	PRICE SENSITIVE	247.58KB	Share
PIQ Ceasing to be a substantial holder
29/11/19		74KB	Share
PIQ Results of Meeting
28/11/19		276.21KB	Share
PIQ Proteomics AGM Presentation
28/11/19		1.06MB	Share
PIQ Change in substantial holding
27/11/19		146.17KB	Share
PIQ Change in substantial holding
26/11/19		116.11KB	Share
PIQ Partnership provides funding for cutting-edge facility
26/11/19	PRICE SENSITIVE	265.78KB	Share
PIQ Completion of Placement
25/11/19		517.68KB	Share
PIQ Proteomics raises $3m in heavily oversubscribed Placement
15/11/19	PRICE SENSITIVE	249.11KB	Share
PIQ Trading Halt
13/11/19	PRICE SENSITIVE	541.2KB	Share
PIQ CE Mark for predictive test for diabetic kidney disease
12/11/19	PRICE SENSITIVE	272.53KB	Share
PIQ Appendix 3B - Exercise of Employee Options
04/11/19		513.81KB	Share
PIQ Appendix 4C - September 2019 Quarterly Report
31/10/19	PRICE SENSITIVE	429.8KB	Share
PIQ Proteomics receives $1.1 million in R&D tax incentive
29/10/19	PRICE SENSITIVE	214.79KB	Share
PIQ Notice of Annual General Meeting/Proxy Form
21/10/19		799.41KB	Share
PIQ PIQ market update
21/10/19		4.63MB	Share
PIQ Change of Director's Interest Notice
01/10/19		108.03KB	Share
PIQ Issue of Shares under Director Fee Plan
01/10/19		396.56KB	Share
PIQ PromarkerD IVD successfully developed and validated
17/09/19	PRICE SENSITIVE	223.04KB	Share
PIQ Trading Halt
16/09/19	PRICE SENSITIVE	683.63KB	Share
PIQ Pause in Trading
16/09/19	PRICE SENSITIVE	117.53KB	Share
PIQ PromarkerD diabetic kidney disease test launched in Spain
13/09/19	PRICE SENSITIVE	232.14KB	Share
PIQ PromarkerD test ready for launch in Europe
12/09/19	PRICE SENSITIVE	284.42KB	Share
PIQ PromarkerD latest results published in peer reviewed journal
10/09/19		262.08KB	Share
PIQ Annual Report to shareholders
30/08/19		7.51MB	Share
PIQ Preliminary Final Report
30/08/19	PRICE SENSITIVE	169.34KB	Share
PIQ Corporate Governance Statement and Appendix 4G
30/08/19		368.76KB	Share
PIQ Appendix 4C - June 2019 Quarterly Report
30/07/19	PRICE SENSITIVE	366.92KB	Share
PIQ PromarkerD secures TGA software approval & Indonesian patent
29/07/19		238.74KB	Share
PIQ Proteomics secures contracts for pharmacokinetic analysis
26/07/19	PRICE SENSITIVE	234.68KB	Share
PIQ Exercise of Options - Secondary Trading Notice & Appendix 3B
26/06/19		527.37KB	Share
PIQ PIQ investor presentation - 121 Tech Investment Hong Kong
13/06/19		865.07KB	Share
PIQ PromarkerD to feature at world's largest diabetes conference
07/06/19		257.46KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 38.0¢		Change 0.000(0.00%)		Mkt cap ! $62.19M

Open	High	Low	Value	Volume
39.0¢	40.0¢	38.0¢	$58.62K	150.4K

Buyers (Bids)

No.	Vol.	Price($)
2	12180	37.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.5¢	5203	1

View Market Depth

No.	Vol.	Price($)
2	12180	0.370
1	36	0.360
2	31937	0.355
2	6428	0.350
1	2898	0.345

Price($)	Vol.	No.
0.385	5203	1
0.400	26318	4
0.410	100000	1
0.425	2775	1
0.440	1983	1

Last trade - 15.42pm 08/08/2025 (20 minute delay)

PIQ (ASX) Chart

PROTEOMICS INTERNATIONAL LABORATORIES LTD - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available